Kiniksa Pharmaceuticals

Kiniksa Pharmaceuticals, Ltd., a biopharmaceutical company, focuses on discovering, acquiring, developing, and commercializing therapeutic medicines for patients suffering from debilitating diseases with significant unmet medical needs worldwide. Its product candidates include ARCALYST, an interleukin-1alpha and interleukin-1beta, for the treatment of recurrent pericarditis, which is an inflammatory cardiovascular disease; Mavrilimumab, a monoclonal antibody inhibitor that completed Phase II clinical trials for the treatment of giant cell arteritis; Vixarelimab, a monoclonal antibody, which is in Phase 2a clinical trial for the treatment of prurigo nodularis, a chronic inflammatory skin condition; and KPL-404, a monoclonal antibody inhibitor of the CD40- CD154 interaction, a T-cell co-stimulatory signal critical for B-cell maturation, immunoglobulin class switching, and type 1 immune response. Kiniksa Pharmaceuticals, Ltd. was incorporated in 2015 and is based in Hamilton, Bermuda.

Our mission is to bring innovative therapeutic options to patients who lack therapeutic options and to extend and improve their quality of life.

Our vision is to be the global leader in developing and commercializing novel therapies for difficult-to-treat diseases.

Kinika Pharmaceuticals has been recognized for a number of achievements including the 2017 Boston Business Journal’s Fast 50 Award, 2018 MassBio Breakthrough Therapy Designation Award, and 2019 Fierce BioTech Breakthrough Therapeutic Designation Award.